AbClon Inc is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
03/11/26	₩17,250.00	-5.89%	112,225
02/11/26	₩18,330.00	-0.76%	69,681
30/10/26	₩18,470.00	-5.81%	288,125
29/10/26	₩19,610.00	-7.06%	302,556
28/10/26	₩21,100.00	0.00%	261,095

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 03/11/2026			5-day change	1st Jan Change
17,250.00 ^KRW	-5.89%		-18.25%	-59.41%

09-20	AbClon Inc.(KOSDAQ:A174900) added to S&P Global BMI Index	CI
06-08	Alligator partner Henlius doses first patients in HLX22 study	FW

Market Cap	344B 256M 229M 210M 191M 358M 24.25B 367M 2.51B 1.01B 12.8B 961M 940M 40.57B	P/E 2024	-14.5x	P/E 2025	-43.5x
Enterprise Value	306B 228M 204M 187M 170M 319M 21.58B 327M 2.23B 898M 11.39B 855M 837M 36.1B	EV / Sales 2024	103x	EV / Sales 2025	164x
Free-Float	80.02%	Yield 2024 *	-	Yield 2025	-

09-20	AbClon Inc.(KOSDAQ:A174900) added to S&P Global BMI Index	CI
06-08	Alligator partner Henlius doses first patients in HLX22 study	FW
05-22	Alligator Bioscience comments on Henlius update for HLX22	FW
04-23	Alligator partner Henlius presents preclinical data for HLX49	FW
04-23	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate	CI
04-07	Abclon wins 396 million won order	RE
03-09	AbClon wins 778 million won order	RE
03-02	Alligator Bioscience: First Patient Dosed in Phase 2/3 Study with HLX22 in China	FW
30/09/25	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.	CI
27/08/25	Abclon wins 309 million won order	RE
20/05/25	Abclon Wins 354 Million Won Order	RE
19/05/25	AbClon Inc To Issue 1.4 Million Common Shares	RE
18/05/25	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.	CI

06-08	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
05-22	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
04-23	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
03-02	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22	AQ
04/12/24	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial	AQ

AbClon Inc. Share Price

Stocks

A174900

KR7174900001

Pharmaceuticals

Valuation: AbClon Inc.

Chart: AbClon Inc.

Latest news: AbClon Inc.

Press Releases: AbClon Inc.

Quotes and Performance

Price Extremes

Managers and Directors: AbClon Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

1 day	-5.89%
1 week	-18.25%
Current month	-6.61%
1 month	-38.17%
3 months	-21.41%
6 months	-64.90%
Current year	-59.41%

1 week	17,250	21,450
1 month	17,250	29,500
Current year	16,250	95,800
1 year	16,250	95,800
3 years	6,810	95,800
5 years	6,810	95,800
10 years	6,810	95,800

Manager	Title	Age	Since
Jong-Seo Lee CEO	Chief Executive Officer	63	24/06/2010
Doo-Hun Kim DFI	Director of Finance/CFO	59	27/03/2024
Jong-Hoon Kim CTO	Chief Tech/Sci/R&D Officer	57	28/03/2023

Director	Title	Age	Since
Jong-Seo Lee BRD	Director/Board Member	63	-
Jung-Ho Kim BRD	Director/Board Member	62	28/03/2021
Jong-Hoon Kim BRD	Director/Board Member	57	28/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCLON INC.	-5.89%	-18.25%	-23.67%	+47.81%	256M
ELI LILLY AND COMPANY	-0.11%	+9.94%	+57.20%	+148.21%	1,255B
JOHNSON & JOHNSON	-1.62%	-0.95%	+42.90%	+75.88%	641B
ABBVIE INC.	-0.98%	-0.14%	+34.93%	+102.23%	505B
ROCHE HOLDING AG	+0.06%	-1.91%	+48.18%	+64.96%	381B
MERCK & CO., INC.	-2.49%	+2.01%	+75.38%	+39.94%	357B
NOVARTIS AG	+0.38%	+2.07%	+29.98%	+56.58%	303B
ASTRAZENECA PLC	-0.68%	+6.86%	+8.88%	+32.74%	286B
AMGEN INC.	-0.90%	+2.97%	+55.67%	+70.93%	249B
GILEAD SCIENCES, INC.	-1.68%	+5.27%	+37.21%	+105.26%	208B
Average	-1.39%	+0.83%	+36.67%	+74.45%	418.55B
Weighted average by Cap.	-0.76%	+3.90%	+46.69%	+93.51%

	2024	2025
Net sales	2.34B 1.74M 1.55M 1.43M 1.3M 2.44M 165M 2.5M 17.05M 6.86M 87.01M 6.53M 6.39M 276M	4.71B 3.51M 3.13M 2.88M 2.61M 4.91M 332M 5.03M 34.35M 13.82M 175M 13.16M 12.88M 556M
Net income	-16.3B -12.12M -10.83M -9.95M -9.04M -16.97M -1.15B -17.4M -119M -47.78M -606M -45.51M -44.54M -1.92B	-17.91B -13.32M -11.9M -10.93M -9.93M -18.64M -1.26B -19.11M -130M -52.48M -666M -49.99M -48.92M -2.11B
Net Debt	-4.61B -3.43M -3.06M -2.82M -2.56M -4.8M -325M -4.92M -33.6M -13.52M -172M -12.88M -12.6M -544M	-37.93B -28.21M -25.2M -23.15M -21.02M -39.48M -2.67B -40.47M -276M -111M -1.41B -106M -104M -4.47B